Combined approach in the diagnostic of Parkinson’s disease
Objective: Our aim was to develop and scientifically substantiate set of criteria for early(preclinical) diagnosis of neurodegenerative disorders with the assessment of a number of…6-[18F]fluoro-L-3,4-dihydroxyphenylalanine (F-DOPA) PET striatal binding patterns in patients with Parkinson’s Disease and Parkinson Plus Syndromes.
Objective: In this study we investigate striatal binding patterns in patients with Idiopathic Parkinson’s disease (IPD), compared to those with Parkinson Plus syndromes (PPS) versus…18f-PI-2620 tau PET neuroimaging, tau protein burden and 18f-PI-2620 tau autoradiography on human postmortem brain tissue in a PSP patient
Objective: Our aim is to describe the findings of 18F-PI-2620 tau-PET imaging, together with tau protein burden and 18F-PI-2620 tau autoradiography in brain tissue from…The monoamine oxidase-B inhibitor selegiline does not affect 18F-Florzolotau uptake in patients with progressive supranuclear palsy: a longitudinal case series
Objective: In a longitudinal case series of patients with progressive supranuclear palsy (PSP), a chronic challenge with the irreversible MAO-B inhibitor selegiline was used to…PET visualization of α-synuclein pathologies in humans using [18F]C05-05
Objective: This study aimed to visualize α-synuclein aggregates in living patients with Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA).…Correlation of clinical profile of Parkinsonism with molecular imaging
Objective: CORRELATION OF CLINICAL PROFILE OF PARKINSONISM WITH MOLECULAR IMAGING (TRODAT AND PET-CT BRAIN) Background: The current study aims to establish the role of Molecular…Longitudinal imaging of regional volumes, presynaptic terminals and glucose metabolism in brains of people with early Huntington’s disease
Objective: To compare the sensitivity of 11C‑UCB‑J PET, 18F-FDG PET and volumetric MRI for detection of longitudinal brain changes in early Huntington’s Disease (HD). Background:…Clinical and functional determinants of motor reserve in patients with de novo Parkinson’s disease
Objective: To determine the clinical determinants and the role of serotonergic innervation on motor reserve in patients with de novo Parkinson's disease. Background: Patients with…The hypometabolism in anterior cingulate gyrus and thalamus: potential biomarkers of disease progression in progressive supranuclear palsy
Objective: This study aimed to identify differences in FDG uptake and metabolic covariant network (independent component analysis) in progressive supranuclear palsy (PSP) in comparison with…Substantia Nigra blood-brain barrier opening in Parkinson´s disease: PET (18F-Choline) evidence of parenchymal penetration
Objective: To evaluate clinical safety, feasibility, and tissue penetration (by 18F-Choline PET) of MR-guided focused ultrasound (MRgFUS) blood-brain barrier opening (BBB-O) of the substantia nigra…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 35
- Next Page »